Innovent Biologics, Inc.（1801.HK）股价、财务与研究

盘中时间采用HKT。市场数据可能有所延迟。

公司概况

Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.

行业: Biotechnology
部门: Healthcare
总部: CN
首席执行官: De-Chao Yu
上市以来: 2018年10月31日
雇员: 7,502

市场位置

52周区间

当前HK$99.50，

HK$69.55HK$109.1

开盘价: HK$99.50
前收盘价: HK$102.4
成交量: 1083.3万; 0.78× 平均值
平均成交量: 1390.93万; 日均成交量
市值: 1732.22亿 HKD
贝塔: 0.23; 市场参考 1
50天平均值: HK$87.78; 高于平均水平+13.35%
200天平均值: HK$85.9055; 高于平均水平+15.82%

财务数据

财务快照

估值与收益率

市盈率（TTM）: 171.32×
市净率（TTM）: 7.54×
市销率（TTM）: 11.39×
股息率: 0.00%

盈利能力和效率

毛利率: 76.42%
营业利润率: 5.63%
净利润率: 6.24%

财务健康

负债权益比: 0.15×
奥特曼 Z 分数: 5.51
皮奥特罗斯基 F 分数: 7 共 9 个

财务报表

利润率趋势

盈利能力占已公布营收的百分比。

毛利率营业利润率净利润率

损益趋势

营收

130.42亿 CNY+38.42%

营业利润

7.34亿 CNY+14.89亿 CNY

净利润

8.14亿 CNY+9.08亿 CNY

项目（CNY）	2025财年	2024财年	2023财年	2022财年	2021财年
营收	130.42亿 CNY	94.22亿 CNY	62.06亿 CNY	45.56亿 CNY	42.7亿 CNY
销货成本	30.44亿 CNY	15.1亿 CNY	18.07亿 CNY	9.31亿 CNY	5.73亿 CNY
毛利	99.98亿 CNY	79.12亿 CNY	43.99亿 CNY	36.25亿 CNY	36.97亿 CNY
研究与开发	26.24亿 CNY	26.81亿 CNY	22.28亿 CNY	28.71亿 CNY	24.78亿 CNY
销售、一般及管理费用	66.4亿 CNY	50.85亿 CNY	38.51亿 CNY	34.26亿 CNY	36.12亿 CNY
营业费用	92.64亿 CNY	76.54亿 CNY	60.79亿 CNY	62.07亿 CNY	57.49亿 CNY
利息收入	4.27亿 CNY	4.23亿 CNY	4.53亿 CNY	1.9亿 CNY	1.52亿 CNY
利息支出	7753.79万 CNY	6764.7万 CNY	9862.4万 CNY	1.02亿 CNY	6246.4万 CNY
折旧和摊销	5.77亿 CNY	2.76亿 CNY	3.85亿 CNY	3.19亿 CNY	2.05亿 CNY
营业利润	7.34亿 CNY	−7.56亿 CNY	−16.79亿 CNY	−31.23亿 CNY	−27.03亿 CNY
净利润	8.14亿 CNY	−9463.1万 CNY	−10.28亿 CNY	−21.79亿 CNY	−27.29亿 CNY